Patients with Lung Cancers Responsive to Immunotherapy Drug Beat Standard Odds of Survival

Reading Time: 1 minutes

More than seven years after the start of one of the first clinical trials of the immunotherapy drug nivolumab, researchers at the Johns Hopkins Kimmel Cancer Center report that the five-year survival estimate for a limited subset of people with advanced nonsmall cell lung cancer taking the drug is 16 percent, compared with a historical survival rate for that group of 1 to 4 percent.

Leave a Reply

Your email address will not be published. Required fields are marked *